Compare BBGI & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBGI | SNSE |
|---|---|---|
| Founded | 1961 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 12.2M |
| IPO Year | 1999 | 2021 |
| Metric | BBGI | SNSE |
|---|---|---|
| Price | $3.70 | $30.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $72.50 |
| AVG Volume (30 Days) | 8.8K | ★ 583.6K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.64 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $232,179,463.00 | N/A |
| Revenue This Year | $5.02 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 69.89 | N/A |
| 52 Week Low | $3.26 | $0.25 |
| 52 Week High | $26.37 | $36.76 |
| Indicator | BBGI | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 40.64 | 63.61 |
| Support Level | N/A | $7.94 |
| Resistance Level | $4.67 | $36.76 |
| Average True Range (ATR) | 0.25 | 2.68 |
| MACD | 0.00 | -0.73 |
| Stochastic Oscillator | 45.07 | 63.30 |
Beasley Broadcast Group Inc is a multi-platform media company, whose primary business is operating radio stations throughout the United States. The company offers local and national advertisers integrated marketing solutions across audio, digital and event platforms. It owns and operates stations in the following markets: Atlanta, GA, Augusta, GA, Boston, MA, Charlotte, NC, Detroit, MI, Fayetteville, NC, Fort Myers-Naples, FL, Las Vegas, NV, Middlesex, NJ, Monmouth, NJ, Morristown, NJ, Philadelphia, PA, Tampa-Saint Petersburg, FL, and Wilmington, DE. The company operates in two segments Audio and Digital.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).